Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (141-150 of 228) with videos related to

Pageof 23
Sort By:
BMC Infectious Diseases|May 28, 2026
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency departmentMarkus Kleinberger, Petar Popov, Anna Pfarrhofer, et al.
Acta Neuropathologica|January 4, 2012
Brain metastases: pathobiology and emerging targeted therapiesMatthias Preusser, David Capper, Aysegül Ilhan-Mutlu, et al.
Wiener Klinische Wochenschrift|May 4, 2022
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of CardiologyJutta Bergler-Klein, Peter P Rainer, Markus Wallner, et al.
Cancer Chemotherapy and Pharmacology|February 8, 2008
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancerRupert Bartsch, Catharina Wenzel, Simon P Gampenrieder, et al.
International Journal of Cancer|February 7, 2022
The impact of COVID-19 on cancer care of outpatients with low socioeconomic statusElisabeth L Zeilinger, Simone Lubowitzki, Matthias Unseld, et al.
Virchows Archiv : an International Journal of Pathology|August 5, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancerMyriam Stolz, Alex Farr, Kristina A Tendl-Schulz, et al.
Breast (Edinburgh, Scotland)|July 15, 2014
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S Berghoff, Rupert Bartsch, Matthias Preusser, et al.
Cancer|July 20, 2023
Risk as a pattern over time: Delineation of time-dependent risk factors in biological, psychological, and social variables in cancer patientsMatthias Knefel, Elisabeth L Zeilinger, Simone Lubowitzki, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2012
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerRupert Bartsch, Zsuzsanna Bago-Horvath, Anna Berghoff, et al.
International Journal of Surgery (London, England)|June 6, 2022
The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center studyMichael Bolliger, Pia Lanmüller, Michael Schuetz, et al.
Pageof 23

Showing results (141-150 of 228) with videos related to

Sort By:
Pageof 23
BMC Infectious Diseases|May 28, 2026
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency departmentMarkus Kleinberger, Petar Popov, Anna Pfarrhofer, et al.
Acta Neuropathologica|January 4, 2012
Brain metastases: pathobiology and emerging targeted therapiesMatthias Preusser, David Capper, Aysegül Ilhan-Mutlu, et al.
Wiener Klinische Wochenschrift|May 4, 2022
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of CardiologyJutta Bergler-Klein, Peter P Rainer, Markus Wallner, et al.
Cancer Chemotherapy and Pharmacology|February 8, 2008
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancerRupert Bartsch, Catharina Wenzel, Simon P Gampenrieder, et al.
International Journal of Cancer|February 7, 2022
The impact of COVID-19 on cancer care of outpatients with low socioeconomic statusElisabeth L Zeilinger, Simone Lubowitzki, Matthias Unseld, et al.
Virchows Archiv : an International Journal of Pathology|August 5, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancerMyriam Stolz, Alex Farr, Kristina A Tendl-Schulz, et al.
Breast (Edinburgh, Scotland)|July 15, 2014
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S Berghoff, Rupert Bartsch, Matthias Preusser, et al.
Cancer|July 20, 2023
Risk as a pattern over time: Delineation of time-dependent risk factors in biological, psychological, and social variables in cancer patientsMatthias Knefel, Elisabeth L Zeilinger, Simone Lubowitzki, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2012
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerRupert Bartsch, Zsuzsanna Bago-Horvath, Anna Berghoff, et al.
International Journal of Surgery (London, England)|June 6, 2022
The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center studyMichael Bolliger, Pia Lanmüller, Michael Schuetz, et al.
Pageof 23